"Everything is pre-clinical right now and there is no guarantee that it will advance to clinical."
Bear, do we know of any pending publications updates?
"In a recent New York Times article published on March 17th, 2020, researchers at the Quantitative Biosciences Institute Coronavirus Research Group, University of California, San Francisco, identified the human bromodomain-containing protein (BRD2) – a direct target of apabetalone – as a critical interaction partner for SARS-CoV-2. Publications are pending." (bolding added)
